Feature | Â | CHEK2-positive cases | CHEK2-negative cases | p |
---|---|---|---|---|
 |  | (n = 252) | (n = 2976) |  |
Age in years (mean) | Â | 44.2 | 44.3 | 0.7 |
Age group | 20–30 | 3.6% (9/252) | 1.7% (52/2976) | 0.07 |
 | 31–40 | 15.9% (40/252) | 17.2% (512/2976) | 0.7 |
 | 41–50 | 80.5% (203/252) | 81% (2412/2976) | 0.9 |
Histology | ductal G1–2 grade | 29.3% (54/186) | 26.9% (622/2315) | 0.6 |
 | ductal G3 grade | 10.7% (20/186) | 12.7% (294/2315) | 0.5 |
 | medullary | 2.1% (4/186) | 4.9% (113/2315) | 0.1 |
 | lobular | 21.5% (40/186) | 15.8% (366/2315) | 0.05 |
 | tubulo-lobular | 4.3% (8/186) | 3.6% (83/2315) | 0.8 |
 | DCIS | 11.3% (21/186) | 7.2% (168/2315) | 0.06 |
 | other | 4.8% (9/186) | 5.1% (118/2315) | 1.0 |
 | missing or unknown | 16.7% (31/186) | 23.8% (551/2315) | 0.03 |
Pre-operative chemotherapy | Â | 27.7% (66/238) | 24.5% (661/2693) | 0.3 |
Oestrogen receptor | positive | 65.1% (97/149) | 63.7% (1048/1646) | 0.8 |
Tumour size (cm) | <1 cm | 5.9% (9/152) | 11.2% (193/1728) | 0.05 |
 | 1–2 cm | 40.1% (61/152) | 45.3% (783/1728) | 0.2 |
 | >2 cm | 53.9% (82/152) | 43.5% (752/1728) | 0.01 |
Lymph nodes | positive | 45.0% (68/151) | 40.1% (722/1777) | 0.3 |
Multicentric | Â | 28.7% (41/143) | 19.5% (316/1619) | 0.01 |
Bilateral | Â | 2.3% (5/215) | 3.3% (84/2531) | 0.6 |
Family history positive* | Â | 13.8% (31/224) | 8.9% (237/2652) | 0.02 |